TickerTalks
Browse all tickers →
TickerTalks›$PYXS
PYPYXS

Pyxis Oncology, Inc.

$PYXS·$167M·Biotechnology·Healthcare
$2.28+2.2%YTD+89.0%1Y+87.4%
Mentions · last 7 days
2026-07-09: 6 posts2026-07-10: 2 posts2026-07-11: 1 posts2026-07-12: 4 posts2026-07-13: 2 posts2026-07-14: 1 posts2026-07-15: 1 posts19-59%
Price updated 11m ago·X counts updated 2d ago
PYPYXS
$PYXSPyxis Oncology, Inc.
$2.28+2.24%19 posts-59%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $PYXS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventCooling offAI verdict · as of 2026-07-17

Catching its breath after a run — could pick back up or fade from here.

Pyxis Oncology at 28% of range with 99.8% gross margin — the specific antibody-drug-conjugate pipeline is the whole thesis.

Pyxis Oncology is a specific clinical-stage antibody-drug-conjugate biotech whose specific pipeline for solid tumors is the whole equity thesis. The stock is up 89% year-to-date on the specific pipeline-catalyst setup.

Where the setup reads:

  • The economics are pre-revenue by design: 99.8% gross margin at -6% operating margin with -59% FCF yield and -173% ROIC — meaning the equity is a pure claim on the specific pipeline milestones arriving.
  • The tape has cooled: sitting 2.6% above the 50-day but 5% below the 200-day at 28% of the 52-week range with volume 63% below average — a coiled setup with specific catalyst approaching.
  • The specific PS ratio at 8x is relatively contained for a pre-revenue biotech — meaning the multiple has room if the pipeline delivers specific milestones.
  • The check is the specific single-catalyst binary risk: with pipeline as the whole story, any specific data disappointment or safety-signal disclosure produces violent unwind.

Aug 13 earnings is the trigger. A number confirming specific pipeline milestone timing plus cash-runway commentary extends the leg materially; a specific timeline slippage or safety-signal disclosure is the specific setup for the acceleration to reverse.

What to watch: The Aug 13 print — pipeline milestone timing, cash-runway update, and any specific data-readout commentary. A specific pipeline calendar extends the leg; a slippage or safety-signal disclosure produces violent give-back.

On the calendar: 2026-08-13 — Q2 earnings

Read the AI verdict + X sentiment for $PYXS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Preclinical biotech developing antibody-drug conjugates (ADCs) targeting novel antigens on solid tumors.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PYXS.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $PYXS

Partial — Preclinical biotech developing antibody-drug conjugates (ADCs) targeting novel antigens on solid tumors; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-173%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-6.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-59.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
8.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-136%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
99.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.6Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-0.37$-0.35-5.7%
Q4 2025Mar 23, 2026$-0.29$-0.35+17.1%
Q3 2025Nov 3, 2025$-0.35$-0.36+2.8%
Q2 2025Aug 14, 2025$-0.30$-0.36+16.7%
Next earningsThu, Aug 13·consensus EPS $-0.34

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.37$-26.0M
Q4 FY25$11.0M—104%-166%$-0.29$-10.4M
Q3 FY25$0———$-0.35$-13.3M
Q2 FY25$2.8M—100%-700%$-0.30$-17.3M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$67K$67K – $67K-$1.22-$1.35 – -$1.128
FY27$4.2M$4.2M – $4.2M-$1.21-$1.34 – -$0.968
FY28$15.8M$15.8M – $15.8M-$1.20-$1.85 – -$0.398
FY29$42.8M$42.8M – $42.8M-$1.01-$1.01 – -$1.017
FY30$114.9M$114.9M – $114.9M-$0.61-$0.61 – -$0.617

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+2.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-4.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 37.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.315-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 30Jakob DupontDirector35.0K sh$107K
+ 10 other (9 awards · 1 exempt) in window

See when $PYXS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 103
AI summary

GordonMD Global Investments LP (Beverly Hills, CA) filed a Form 3 as a new 10% owner and Director of Pyxis Oncology, Inc., reporting shared beneficial ownership of 6,468,999 shares with an event date of June 30, 2026. The form reflects both 10% owner and director status for GordonMD. A new 10%+ investor achieving board representation at Pyxis Oncology is material — this indicates a significant strategic investor taking an active governance role at the clinical-stage oncology company.

8-KMaterial agreementJul 28-K — Item 1.01: Material agreement · Item 3.02: Unregistered equity sale · Item 7.01: Press release / Reg FD
AI summary

Pyxis Oncology entered a private placement securities purchase agreement for 19,600,153 shares at $2.551/share plus accompanying common warrants for an equal number of shares at $3.289 exercise price, raising approximately $50M gross. Dilutive PIPE for this clinical-stage oncology company with warrant coverage adding further potential dilution.

8-KShareholder voteJun 158-K — Item 5.07: Shareholder vote
AI summary

Pyxis Oncology, Inc. (PYXS) reported annual meeting vote results (Item 5.07) in an 8-K filed June 15, 2026. Body unavailable — excerpt cuts off before vote tallies are disclosed.

8-K/AOfficer or director change (amended)Apr 308-K/A — Item 5.02: Officer or director change
AI summary

PYXS disclosed a personnel change (8-K Item 5.02, dated 2026-04-30). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KPress release / Reg FDMar 238-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PYXS reported period ending 2026-03-23 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

+ 11 other (3 13Gs · 2 earnings 8-Ks · 2 proxys · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestonesglobenewswire.com·17d agoPyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestonesglobenewswire.com·64d agoPyxis Oncology to Participate in Upcoming Investor Conferencesglobenewswire.com·65d agoPyxis Oncology Appoints Nelson Azoulay as Chief Business Officerglobenewswire.com·71d agoPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026globenewswire.com·91d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · last 7 days

No standout posts about $PYXS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport